LAM LAB. EDIZIONE SUD - LABORATORIO DI IDEE E PRATICA CLINICA

1. 1.Francesco Tarantini et al.. Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?. Tarantini F, Contento C, Vigna E, Carluccio V, Greco G, Pasciolla C, Ciuffreda L, Rossi G, Urbano MA, D'Ambrosio A, Aprile L, Gagliardi VP, Delia M, Attolico I, Carluccio P, Federico V, Bruzzese A, Di Renzo N, Gentile M, Tarantini G, Mele A, Guarini A, Melillo LMA, Carella AM, Pastore D, Frigeri F, Maggi A, Cumbo C, Specchia G, Musto P, Albano F. Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? Ann Hematol. 2026 Jan 11;105(1):1. doi: 10.1007/s00277-026-06737-3. PMID: 41521357; PMCID: PMC12791063.. 2026
   Articolo scientificoTarantini F, Contento C, Vigna E, Carluccio V, Greco G, Pasciolla C, Ciuffreda L, Rossi G, Urbano MA, D'Ambrosio A, Aprile L, Gagliardi VP, Delia M, Attolico I, Carluccio P, Federico V, Bruzzese A, Di Renzo N, Gentile M, Tarantini G, Mele A, Guarini A, Melillo LMA, Carella AM, Pastore D, Frigeri F, Maggi A, Cumbo C, Specchia G, Musto P, Albano F. Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? Ann Hematol. 2026 Jan 11;105(1):1. doi: 10.1007/s00277-026-06737-3. PMID: 41521357; PMCID: PMC12791063.Leggi il PDF gratuito
2. 2.Cosimo Cumbo et al.. Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications. Cumbo C, Tarantini F, Parciante E, Anelli L, Zagaria A, Biondi G, Caratozzolo MF, Orsini P, Coccaro N, Tota G, Redavid I, Conserva MR, Minervini A, Minervini CF, Gagliardi VP, Delia M, Marzano F, Telegrafo C, Cox SN, Natalicchio A, Balech B, Tullo A, Gentile M, Giorgino F, Specchia G, Musto P, Albano F. Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications. Cancer Gene Ther. 2026 Jan;33(1):169. doi: 10.1038/s41417-025-00982-w. Erratum for: Cancer Gene Ther. 2025 Sep;32(9):963-972. doi: 10.1038/s41417-025-00939-z. PMID: 41184597; PMCID: PMC12791006.. 2026
   Articolo scientificoCumbo C, Tarantini F, Parciante E, Anelli L, Zagaria A, Biondi G, Caratozzolo MF, Orsini P, Coccaro N, Tota G, Redavid I, Conserva MR, Minervini A, Minervini CF, Gagliardi VP, Delia M, Marzano F, Telegrafo C, Cox SN, Natalicchio A, Balech B, Tullo A, Gentile M, Giorgino F, Specchia G, Musto P, Albano F. Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications. Cancer Gene Ther. 2026 Jan;33(1):169. doi: 10.1038/s41417-025-00982-w. Erratum for: Cancer Gene Ther. 2025 Sep;32(9):963-972. doi: 10.1038/s41417-025-00939-z. PMID: 41184597; PMCID: PMC12791006.Leggi il PDF gratuito
3. 3.Mario Delia et al.. How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax. Delia M, Gagliardi VP, Tarantini F, Strippoli L, Ruga L, Attolico I, Carluccio P, Albano F, Musto P. How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax. Br J Haematol. 2026 Jul;209(1):340-343. doi: 10.1111/bjh.70569. Epub 2026 Jun 8. PMID: 42257484.. 2026
   Articolo scientificoDelia M, Gagliardi VP, Tarantini F, Strippoli L, Ruga L, Attolico I, Carluccio P, Albano F, Musto P. How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax. Br J Haematol. 2026 Jul;209(1):340-343. doi: 10.1111/bjh.70569. Epub 2026 Jun 8. PMID: 42257484.Leggi il paperCerca versione gratuita

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).